BioInItaly Newsletter

La vetrina del biotech italiano all’estero


11 mag, 2017

AstraZeneca and Pieris Pharmaceuticals collaborate to develop and commercialise Anticalin-based inhaled treatments for respiratory diseases
AstraZeneca today announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung. Under the collaboration, Pieris will be responsible for advancing its preclinical lead candidate, PRS-060 into Phase I clinical trials in 2017. PRS-060 is an Anticalin against interleukin-4 receptor alpha (IL-4Ra) with potential in asthma. AstraZeneca will fund all clinical development and subsequent commercialisation programmes and Pieris has the option of co-development and co-commercialisation in the US from Phase IIa onwards. In addition, the parties will collaborate to progress four additional novel Anticalins against undisclosed targets for respiratory disease. More info:

MolMed and Megapharmenter into a license and distribution agreement for Zalmoxis® in Israel
MolMed and Megapharm announce they signed a distribution and license agreement which defines all terms and conditions for the supply, registration, promotion and distribution of Zalmoxis in Israel, as anticipated on December 1 2016, when the companies signed a term sheet defining the main terms and conditions. Zalmoxis is conditionally authorised by the European Commission for adult patients affected by leukaemia or other high-risk haematological malignancies, and is the first patient-specific cell therapy used in combination with haplo-identical haematopoietic stem cell transplant (haplo-HSCT). Under the terms and conditions of today’s agreement Zalmoxis will be distributed and marketed by Megapharm, once approved by the Israeli Ministry of Health (MOH) and included in the Israeli National Health Basket of drugs by the MOH. Furthermore, Megapharm will be responsible for conducting all regulatory activities after marketing authorisation in Israel, including market access and price & reimbursement. More info:

Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada
Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada, today announced a strategic agreement to commercialize Xadago® (safinamide) for the treatment of Parkinson’s disease in Canada. Under the terms of the agreement, Valeo Pharma will be responsible for all regulatory, sales and marketing, quality, and distribution activities in Canada. Valeo Pharma will pay Zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales. More info:

Novamont: 100% success in test on the use of biodegradable carrier bags in anaerobic digestion plants in Germany
Novamont commissioned IGlux Witzenhausen GmbH and Witzenhausen-Institut GmbH to conduct a scientific study into the behaviour of biodegradable carrier bags made from MATER-BI – the bioplastic made by Novamont – in German anaerobic digestion plants. The use of biodegradable bags made from MATER-BI was tested in a procedure which encompassed the entire process using equipment made by four different companies: Kompogas, Thoeni, Bekon and WTT. The bags were monitored during pre-treatment, anaerobic digestion, post-composting and maturation at each plant. The percentage by weight of MATER-BI in the input material was between 3.5% and 3.8%. Degradation began during the anaerobic stage and was completed during composting. In total the process took between five and ten weeks, depending on the plant. No MATER-BI residue was found in any of the samples examined at the end of the test, demonstrating that it had completely degraded in all four plants. More info:

Diasorin receives authorization for the distribution of zika IgM test in Europe
DiaSorin (FTSE Italia Mid Cap: DIA) is pleased to announce that it has received the authorization for the distribution of LIAISON® XL Zika Capture IgM assay in Europe. After the Emergency Use Authorization (EUA) received in the United States some weeks ago, DiaSorin will also now start to distribute the Zika IgM test in Europe. LIAISON® XL Zika Capture IgM assay is the first-of-its-kind fully-automated serology assay for the detection of Zika virus infections. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis, or red eyes. The illness usually is mild with symptoms lasting for several days to a week. People typically do not get sick enough to require hospitalization and they very rarely die of Zika: however, the virus infection during pregnancy can cause a serious birth defect called microcephaly, as well as other severe fetal brain defects. Funding for the LIAISON® XL Zika Capture IgM assay was provided by the U.S. Department of Health and Human Services, which granted DiaSorin a $2.6 million contract in the fall of 2016. More info: